Flecainide (Q40612194)

22 September 2017

1 reference

title

Flecainide (English)

1 reference

22 September 2017

Falk RH

1

1 reference

22 September 2017

Fogel RI

series ordinal

2

1 reference

22 September 2017

publication date

1 November 1994

1 reference

Journal of Cardiovascular Electrophysiology

22 September 2017

published in

1 reference

22 September 2017

volume

5

1 reference

22 September 2017

issue

11

1 reference

22 September 2017

page(s)

964-981

1 reference

Discovery and development of flecainide

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Sodium channel block produces opposite electrophysiological effects in canine ventricular epicardium and endocardium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Effect of drugs in the Wolff-Parkinson-White syndrome. Importance of initial length of effective refractory period of the accessory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

21 January 2018

Metabolism of flecainide

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Oral flecainide pharmacokinetics in patients with impaired renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Effects of flecainide on ventricular function: clinical and experimental correlations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Experience with electrophysiologically guided therapy of ventricular tachycardia with flecainide: summary of long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Acute pharmacologic conversion of atrial fibrillation and flutter: the role of flecainide, propafenone, and verapamil

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Reversal of proarrhythmic effects of flecainide acetate and encainide hydrochloride by propranolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Flecainide-induced ventricular tachycardia and fibrillation in patients treated for atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

Life-threatening flecainide toxicity. A pharmacodynamic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1540-8167.1994.TB01136.X

10.1111/J.1540-8167.1994.TB01136.X

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference